EP1438976A4 - Hydrogel biocompatible polyfonctionnel et procede de production associe - Google Patents
Hydrogel biocompatible polyfonctionnel et procede de production associeInfo
- Publication number
- EP1438976A4 EP1438976A4 EP01274505A EP01274505A EP1438976A4 EP 1438976 A4 EP1438976 A4 EP 1438976A4 EP 01274505 A EP01274505 A EP 01274505A EP 01274505 A EP01274505 A EP 01274505A EP 1438976 A4 EP1438976 A4 EP 1438976A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- acrylamide
- hydrogel
- water
- bis
- ethylene bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
- C08K5/0025—Crosslinking or vulcanising agents; including accelerators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/02—Elements
- C08K3/08—Metals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S524/00—Synthetic resins or natural rubbers -- part of the class 520 series
- Y10S524/916—Hydrogel compositions
Definitions
- the organism is mammals.
- ne ⁇ b ⁇ dimymi 25 ne ⁇ b ⁇ dimymi ⁇ izi ⁇ - ⁇ imiches ⁇ imi ( ⁇ edelennaya ⁇ l ⁇ n ⁇ s ⁇ and ⁇ imiches ⁇ aya ine ⁇ n ⁇ s ⁇ , s ⁇ s ⁇ bn ⁇ s ⁇ ⁇ usad ⁇ e or nabu ⁇ aniyu ⁇ sle ⁇ mescheniya in ⁇ ganizm) and bi ⁇ l ⁇ giches ⁇ imi (bi ⁇ l ⁇ giches ⁇ aya ine ⁇ n ⁇ s ⁇ in chas ⁇ n ⁇ s ⁇ i, ⁇ su ⁇ s ⁇ vie ⁇ ea ⁇ tsii ⁇ zhoniya or in ⁇ y ⁇ anev ⁇ y ⁇ ea ⁇ tsii) sv ⁇ ys ⁇ vami. Otherwise, the material must have a format suitable for introducing it into the muscle tissue with minimal trauma for the patient’s organism.
- hydrogels on the main polylamide may be used. Izves ⁇ en gid ⁇ gel on ⁇ sn ⁇ ve s ⁇ lime ⁇ a a ⁇ ilamida me ⁇ ilen- with bis-a ⁇ ilamid ⁇ m in ⁇ aches ⁇ ve sshivayuscheg ⁇ agen ⁇ a, ⁇ isanny in ⁇ a ⁇ en ⁇ e ⁇ ⁇ e 2114578, for ⁇ ednaznachenny izg ⁇ vleniya ⁇ us ⁇ ali ⁇ a eyes s ⁇ de ⁇ zhaschy a 1: 1 0 wt.% And s ⁇ lime ⁇ a a ⁇ ilamida me ⁇ ilen 5-bis a ⁇ ilamida, in vzya ⁇ y ⁇ by weight of 100: 2.26, and 89 by weight of% of physiological production.
- P ⁇ i e ⁇ m ⁇ tsess s ⁇ lime ⁇ izatsii ⁇ v ⁇ dya ⁇ in ⁇ dnu s ⁇ adiyu, z ⁇ in ⁇ aches ⁇ ve ⁇ e ⁇ sidny ⁇ initsia ⁇ v ⁇ lime ⁇ izatsii is ⁇ lzuyu ⁇ mixture ⁇ e ⁇ sul ⁇ a ⁇ a amm ⁇ niya and ⁇ e ⁇ ame ⁇ ile ⁇ ilendiamina, and ⁇ aches ⁇ ve v ⁇ dn ⁇ y s ⁇ edy be ⁇ u ⁇ a ⁇ i ⁇ gennuyu v ⁇ du or ⁇ as ⁇ v ⁇ ⁇ l ⁇ ida na ⁇ iya.
- the hydrogel obtained by this method has an insufficient degree of crosslinking, which is due to the low temperature mode of operation
- the process of sompolimerization and its one-stage E ⁇ ⁇ iv ⁇ di ⁇ ⁇ bys ⁇ mu ⁇ as ⁇ aniyu s ⁇ edini ⁇ eln ⁇ y ⁇ ani in im ⁇ lan ⁇ i ⁇ vannny gel and ⁇ eg ⁇ bys ⁇ y usad ⁇ e and ⁇ ez ⁇ btsii ( ⁇ . ⁇ . ⁇ ek ⁇ eg e ⁇ .
- the hydrogel produced by this method contains unrelated molecules of methylethylenediamine, free ⁇ 2 radicals and a small amount of 1, it means 1 E ⁇ m ⁇ zhe ⁇ vyzyva ⁇ a ⁇ ivnuyu ase ⁇ iches ⁇ uyu v ⁇ s ⁇ ali ⁇ elnuyu ⁇ ea ⁇ tsiyu on ⁇ anney s ⁇ adii introduction gid ⁇ gelya in ⁇ ganizm (see. ⁇ . ⁇ ek ⁇ eg e ⁇ a ⁇ " ⁇ es ⁇ aYe ⁇ u ⁇ g ⁇ Shs ⁇ uasgu ⁇ at ⁇ e de ⁇ ⁇ gtasgu ⁇ a ⁇ zzie gez ⁇ ze!
- a hydrogel gel described in the patent 21 ° 2127129, containing 1, 0 to 8.0 wt.%, Is obtained, which contains a total of 99% of the total weight of 92% of the product. .
- the method of obtaining this material is also described in
- a further one task is to reduce the tissue response of the body to the implant by reducing the content of free radicals and cartridges in the hydraulic gel.
- 15 P ⁇ s ⁇ avlennye problem ⁇ esheny ⁇ em, ch ⁇ ⁇ edl ⁇ zhen ⁇ li ⁇ un ⁇ tsi ⁇ nalny bi ⁇ s ⁇ vmes ⁇ imy gid ⁇ gel, s ⁇ de ⁇ zhaschy ⁇ e ⁇ echn ⁇ -sshi ⁇ y s ⁇ lime ⁇ a ⁇ ilamida s ⁇ crosslinking agen ⁇ m and v ⁇ du, ⁇ y, s ⁇ glasn ⁇ iz ⁇ b ⁇ e ⁇ eniya in ⁇ aches ⁇ ve sshivayuscheg ⁇ agen ⁇ a s ⁇ de ⁇ zhi ⁇ mixture ⁇ , ⁇ '- me ⁇ ilen bis a ⁇ ilamida, ⁇ , ⁇ ' - ethylene-bis-acrylamide and 20% of the angle for the following ratio of weight percentages:
- the indicated biocompatible hydrogel contains bi-distilled and odorogenic water.
- the compatible hydrogel has a pH of 3.5-7.5.
- the indicated crosslinked compound is from 2.0 to 5 to 15.0 wt.% Of the total weight of the hydrogel.
- the indicated biocompatible hydrogel contains the following ratio of components in wt.%:
- the indicated biocompatible hydrogel may also contain the following ratio of components in wt.%: 15 Ukrilamida - 1, 3 - 15,
- the method may also be implemented when in stock.
- a crosslinking agent takes a mixture of ⁇ , ⁇ '- methylene bis acrylamide, ⁇ , ⁇ '- ethylene bis acrylamide, polyvinyl, vinylpyrrolidene and / or ethylene bis
- the gel is washed in hot water, which has a temperature of 70-110 ° C, for at least 3 hours, at a weight of 8-10: ⁇
- Green As a part of the initiative for the elimination of the charge, you must not consume water and / or 20 ammonia in quantities not exceeding 0.33 wt.% Of the total weight of the original.
- bidistilled and hazardous water is available.
- ⁇ a ⁇ izves ⁇ n ⁇ ma ⁇ e ⁇ ial as gid ⁇ gelya on ⁇ sn ⁇ ve s ⁇ lime ⁇ a 25 a ⁇ ilamida and sshivayuschi ⁇ agen ⁇ v ⁇ eds ⁇ avlyae ⁇ s ⁇ b ⁇ y ⁇ e ⁇ me ⁇ nuyu se ⁇ ⁇ e ⁇ echn ⁇ -sshi ⁇ g ⁇ s ⁇ lime ⁇ a a ⁇ ilamida s ⁇ crosslinking agen ⁇ ami in yachey ⁇ a ⁇ ⁇ y ude ⁇ zhivae ⁇ sya v ⁇ dnaya s ⁇ eda in ⁇ y s ⁇ de ⁇ zhi ⁇ sya ne ⁇ e neus ⁇ an ⁇ vlenn ⁇ e ⁇ liches ⁇ v ⁇ nesvyazann ⁇ g ⁇ initsia ⁇ a ⁇ lime ⁇ izatsii, ⁇ a ⁇ ⁇ a ⁇ ne ⁇ e, ⁇ a ⁇ zhe neu
- FIG. 16 - Hydro-gel absorbing method is a product available in the Russian Federation for Patent 21 ° 2127129 under the name “story ⁇ endeavour ⁇ ⁇ » »» ”; For example, they are made in the region of 4000-500 cm “1.
- the product extract is provided with a 5 hydrogel
- a photograph of a histologically-logged biopsy of a tissue of a cassia taken after 30 days of a free delivery is provided, which is available for use (200); 20 ig. 36 - phytogroup of a histological and biological biopsy of the shell, taken after 30 days after a direct injection of the hydrophobic gel “bypass”; in Fig. 4a, a photograph of a histologically harmless biopsy of a dog, taken after 9 months after a prompt injection of a hydro-pump, is provided;
- Fig. 4b phytogroup of histological and biological damage of a dog, taken after 9 months after a direct injection of the hydrophobic gel “bypass”; on ⁇ ig.5a ⁇ eds ⁇ avlena ⁇ g ⁇ a ⁇ iya gis ⁇ l ⁇ giches ⁇ g ⁇ s ⁇ eza bi ⁇ sii z ⁇ ⁇ ani chel ⁇ ve ⁇ a, vzya ⁇ y che ⁇ ez 12 months ⁇ sle subglandulya ⁇ n ⁇ y im ⁇ lan ⁇ atsii ⁇ edlagaem ⁇ g ⁇ gid ⁇ gelya for mamma ⁇ las ⁇ i ⁇ i ( ⁇ as ⁇ a gema ⁇ silin-e ⁇ zin ⁇ m, x 400), where ⁇ - s ⁇ edini ⁇ eln ⁇ annaya ⁇ a ⁇ sula,
- ⁇ - transcendental zone C is a fragment of a hydrogel
- ⁇ is a macrophage on the part of the capsule, a part of the implant
- the product is: - ⁇ rilamide (asgu ⁇ at ⁇ e): ⁇ 3 ⁇ ⁇ ⁇ , mol. weight 71.08, white crystalline product without a deposit; melting point 84.5 ° C; w ⁇ izv ⁇ ds ⁇ v ⁇ ⁇ i ⁇ my ⁇ dta ( ⁇ a ⁇ al ⁇ g " ⁇ ea ⁇ ivy for bi ⁇ imii and issled ⁇ vany in ⁇ blas ⁇ i es ⁇ es ⁇ venny ⁇ nau ⁇ » ⁇ , 1999, p 47, ⁇ a ⁇ al ⁇ zhny ⁇ ° ⁇ 8887.);
- the process is as follows: 15 For the preparation of a reactive mixture, bidistilled and antigenic water having a pH of 5.6 is taken.
- acrylamide and cross-linking agents for example, mixtures of ⁇ , ⁇ '-methylene-bis-acrylamide, ⁇ , ⁇ -ethylene-bis-acrylamide and a slight increase in the amount of 65 5: 0.2 - 6.5: 0.2 - 34.0: 0.1 - 3.0), or a mixture of ⁇ , ⁇ '-methylene bis acrylamide, ⁇ , ⁇ '-ethylene bis acrylamide , price, vinyl pyridolide or ethylene bis- (hydroxyethylenitrile) -acetate acid, or the sum of the last (taken in the given mass ratio at: 0.2 - 6.0: 6.0 - 6.0: - 6.0 - 6.0 0: 0.1 - 3.0: 0.1-2.5), and for this 25, the total mass of the original components in the industry is 2.0-15.0%. (Aromatic quantities in the mixture produce a hydrogel of different density and elasticity).
- the ready-to-use mixture is filtered through bactericidal suitable filters, for example, brand ⁇ 8273 with a size of 5 0.45 ⁇ , which is a unit of 90 °. After this incubation
- the level of dosing is not higher than 1, 0 (mg of dosing per 1 liter).
- the migration of the drug was no more than 0.12 mg / l and at a permissible level of 200 mg / l in drinking water;
- hydrogel For the production of hydrogel, 384 ml of bidistilled apirogenic water with a pH of 5.6 were taken and 13 g of acrylamide, 0.5 g of ⁇ , ⁇ '-methylene bis-acylamide, 2,3- ⁇ - ⁇ , and 0.2 g of rivals, ideal for biological purposes. Then in the original
- the resulting hydrogel was sterilized by autoclaving (at a temperature of 120 ° ⁇ and a pressure of 1, 2 atm.) For 20 minutes.
- Index of application for the methodology described in the "Medicine for Physical Chemistry", ⁇ ., 1974, pp.
- the resulting sample of the hydrogel had the following physical and chemical 15 characteristics:
- the present look is a colorless, polished, intense gel
- the level of dispersion is 0.1 (mg of bromine per 1 liter).
- tissue blocks 20 were fixed at 96 ° ethyl alcohol or neutral raspberry and poured into a paraffin.
- the capsule ⁇ (Fig. For) remains in the market. It is a large part of the connective tissue, the quantity of fibroids decreases in size, and in the remaining cells, the content of ⁇ ( ⁇ ) decreases. ⁇ The reserved area ⁇ Fragments from the gel remain, which are disposed of by the macrophages. The internal capsule rotation was partially sent out by the macros. ⁇ satin worship The following sections (60 and 90 days) of the capsule structure are not
- junction capsule around the implant is thicker than implantation of the claimed material.
- the internal capsule has a large number of malfunctioning and there is no significant loss of memory
- hydrogel - ontropypa (osteochemistry of hematoxylsine-eosin, ⁇ 400).
- this photo gel As can be seen from this photo gel, it is equipped with connecting rods, connecting fibers, markers, leukocytes, and separate neutral leukemia. Partial lysis of the gel and its resorption is noted.
- the “old” fibrous capsule is almost always reversed.
- the implant is equipped with a closed connective-cassule ⁇ without an internal fibroblastic word, which has a place in the cavity of the silicone.
- connecting-cable rods categories, markers, and short-circuit immunity waves
- Part of the methods has a large penile cytoplasm (active phagosis).
- the connecting tissue knit separates the gel near the capsule into fragments.
- hydrogel For the production of hydrogel, 870 ml of bidistilled apirogenic water, having ⁇ , 5, 6, was dissolved in it; 81; acrylamide, 1 1, 5 g, bis-acrylamide, 4.6 grams of alcohol. Then, in the initial solution, 8 ml of 15 mg of water were added to initiate the polymerization. The resulting mixture was filtered, as described in step 1, and placed on an incubation of 80 ° C for 2 hours, then we washed the gel at a standstill of 80 5 hours at a temperature of 125 ° C. 20 The resulting hydraulic gel was sterilized, as described in Example 1.
- Hydrogel had the following physical and chemical characteristics, which were divided in accordance with the methods indicated in Example 1:
- the present view is a palpable mild yellow gel; 25 Indication of investments - 1, 336; ⁇ - 4.0;
- the content of monomers of acrylamide and bisacrylamide is up to 0.4 ⁇ civil;
- the level of dispersion is 0.9 (mg of bromine per 1 liter); Bacteriostatic properties
- hydrogel gel was used for the plasticization of the external muscle. Hydrogel gel in a volume of 50 ml. was injected into the external muscle of a patient I., 42 years old, to eliminate the defect after an irradiated injury. The patient was observed in the aftercare period of 6 months. There were no distant phenomena and no currents. Gel was not available. The simplicity was achieved.
- Example 3. 5 For the production of the hydrogel, 972 ml of bidistilled apirogenic water with a pH of 5.6 was taken, 22.5 g acrylamide, 0.375 g ⁇ , ⁇ '-methylene bis--b réelle ⁇ - acrylamide, 0.06 g of poison and 0.065 g of ethylene bis (hydroxyethylenitrile) - tetracycide acid. Then, 2.5 g of ammonia sulfate was introduced into the original solution.
- Hydrogel had the following physical and chemical characteristics, which were divided in accordance with the methods indicated in Example 1:
- the present look is a colorless gel; 20 Indication of investments - 1, 334; ⁇ - 6.8;
- the content of the acromilamides is absent;
- the level of dispersion is 0.15 (mg of bromine per 1 liter).
- the pressure zone of bacteria growth is 1, 5 mm.
- hydrogel samples were implanted in a convenient dog and removed after 3 and 6 months.
- the proposed hydrogel which contains, as a crosslinking agent, a mixture of ⁇ , ⁇ '-methylene-bis-acrylamide, ⁇ , ⁇ -ethylene bis-5 acrylamide and 4 months of age, is 6 months old. 15% of water is consumed;
- the proposed hydrogel containing a cross-linking agent as a mixture of ⁇ , ⁇ '-methylene bis-acrylamide, ⁇ , ⁇ -ethylene bis acrylamide, ileus, and is non-toxic. 5% of water is consumed by implants, and after 6 months, 9% of water is consumed after implantation.
- a dry gel with a low dry content of up to 3% is easy to inject through the thinned needles and can be used to lay soft tissues.
- a dry gel with a low dry content of up to 3% is easy to inject through the thinned needles and can be used to lay soft tissues.
- the resulting hydrogel was used to maintain a handy patch and remove facial wrinkles. Hydrogel gel in a volume of 1 ml. a total of 47 years was introduced. The patient was observed in the after-treatment period for 12 months with periodic treatment times in one month. Distinctive and allergic phenomena have not been established. c. The desired cosmetic effect has been achieved.
- the resulting hydraulic gel was sterilized by autoclaving, as described in Example 1.
- the material had the following physical and chemical characteristics: its present appearance is a colorless, highly opaque, polucheznaya gel;
- composition of monomers 0.04 ⁇ transaction; 15
- the level of breakdown is 0.05 (mg of bromine per 1 liter).
- Bacteriological properties the pressure zone of bacteria growth is 2.0 mm.
- the resulting hydrogel was used to remove overspray. Hydrogel in the amount of 2 g was introduced by the patient, 27 years. Patient 20 was observed in the after-treatment period for 12 months with periodic treatment times in one month. There were no distant phenomena and no currents. The desired cosmetic effect has been achieved.
- hydrogel For the production of the hydrogel, 375 ml of bidistilled organic water was taken at a pH of 5.6, and 23.75 g of acrylamide, 1, 075 g ⁇ , ⁇ '-methylene-bis-aqylamide, 0.1, 0,1-methylamide, 0.1 were dissolved in it. , 0.03g. Then, 0.02 g of ammonium sulfide and 1 ml of 30% hydrogen peroxide were introduced into the initial solution. The resulting mixture was filtered, as described in Example 1, and placed on incubation Temp. 50 ° C for 16 hours, then wash the gel in 3.5 l of hot water and temperature 100 ° C for 4.0 hours and incubate another 1 hour at 130 ° C.
- the resulting hydraulic gel was sterilized by autoclaving, as described in Example 1.
- the material had the following physical and chemical characteristics: Appearance - colorless gel; The indicator of investments - 1, 348; ⁇ - 4.8; Density - 1, 0g / cm 3 ;
- the proposed hydrogel practically does not cause tissue reaction, does not cause sensitization of the organism, does not cause Disruptive and non-critical changes and may be used for endoprosthesis and commercial soft tissue repair, as well as for endorsement of the parts and accessories Compared with a known hydrogel -
- the proposed hydrogel has a lower low-tissue response of the organism to its implantation, a higher rate of implantation, and a lower degree of amenity.
- P ⁇ edlagaemy gid ⁇ gel m ⁇ zhe ⁇ by ⁇ is ⁇ lz ⁇ van ⁇ a ⁇ zhe in ⁇ aches ⁇ ve na ⁇ lni ⁇ elya ⁇ i izg ⁇ vlenii end ⁇ ez ⁇ v, s ⁇ de ⁇ zhaschi ⁇ ⁇ b ⁇ l ⁇ ch ⁇ u and na ⁇ lni ⁇ el and ⁇ a ⁇ zhe in ⁇ aches ⁇ ve de ⁇ for le ⁇ a ⁇ s ⁇ venny ⁇ ⁇ e ⁇ a ⁇ a ⁇ v ⁇ i dli ⁇ eln ⁇ m medi ⁇ amen ⁇ zn ⁇ m treatment na ⁇ ime ⁇ , ⁇ u ⁇ ley or abstsess ⁇ v and ⁇ aches ⁇ ve n ⁇ si ⁇ elya for ⁇ ul ⁇ ivi ⁇ vaniya ⁇ le ⁇ chel ⁇ ve ⁇
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Colloid Chemistry (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RU2001/000392 WO2003026711A1 (fr) | 2001-09-28 | 2001-09-28 | Hydrogel biocompatible polyfonctionnel et procede de production associe |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1438976A1 EP1438976A1 (fr) | 2004-07-21 |
EP1438976A4 true EP1438976A4 (fr) | 2007-04-18 |
EP1438976B1 EP1438976B1 (fr) | 2007-12-19 |
Family
ID=20129652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01274505A Expired - Lifetime EP1438976B1 (fr) | 2001-09-28 | 2001-09-28 | Hydrogel biocompatible polyfonctionnel et procede de production associe |
Country Status (12)
Country | Link |
---|---|
US (1) | US7294348B2 (fr) |
EP (1) | EP1438976B1 (fr) |
CN (1) | CN1257752C (fr) |
AT (1) | ATE381356T1 (fr) |
BR (1) | BR0117137B1 (fr) |
CA (1) | CA2461821C (fr) |
DE (1) | DE60132025T2 (fr) |
DK (1) | DK1438976T3 (fr) |
ES (1) | ES2298195T3 (fr) |
MX (1) | MXPA04002967A (fr) |
RU (1) | RU2205034C1 (fr) |
WO (1) | WO2003026711A1 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0303798D0 (en) * | 2003-02-19 | 2003-03-26 | Bioartem Ltd | Gel |
GB0327310D0 (en) * | 2003-11-24 | 2003-12-24 | Oztech Pty Ltd | Pressure impulse mitigation |
DE102007040370B4 (de) * | 2007-08-20 | 2011-06-16 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Kollagenhaltiger Zellträger |
DE102009005534B3 (de) * | 2008-12-18 | 2010-04-01 | Heraeus Medical Gmbh | Sporozide Zusammensetzungen und deren Verwendung |
US11090387B2 (en) | 2008-12-22 | 2021-08-17 | The Trustees Of The University Of Pennsylvania | Hydrolytically degradable polysaccharide hydrogels |
US9486404B2 (en) * | 2011-03-28 | 2016-11-08 | The Trustees Of The University Of Pennsylvania | Infarction treatment compositions and methods |
RU2499003C1 (ru) * | 2012-03-22 | 2013-11-20 | Федеральное государственное бюджетное учреждение науки Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (ИНХС РАН) | Способ получения полиакриламидного гидрогеля |
RU2493173C1 (ru) * | 2012-03-22 | 2013-09-20 | Федеральное государственное бюджетное учреждение науки Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (ИНХС РАН) | Способ получения полиакриламидного гидрогеля |
AU2013300171B2 (en) * | 2012-08-09 | 2017-09-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for preparing biological specimens for microscopic analysis |
RU2545806C1 (ru) | 2013-12-26 | 2015-04-10 | Международная коммерческая компания "НЬЮКРОСС ВЕНТУРЕС ЛТД" | Материал медицинского назначения "матрексин" на основе полиакриламидного гидрогеля и способ его получения (варианты) |
EP3125218A4 (fr) * | 2014-03-24 | 2017-04-12 | Fujifilm Corporation | Composition de gel aqueux pour fantôme d'organe et fantôme d'organe |
AU2015266894A1 (en) | 2014-05-30 | 2016-08-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and devices for imaging large intact tissue samples |
WO2017096248A1 (fr) * | 2015-12-02 | 2017-06-08 | Clearlight Diagnostics Llc | Procédés de préparation et d'analyse d'échantillons de tissu tumoral pour la détection et la surveillance de cancers |
US11254974B2 (en) | 2016-02-10 | 2022-02-22 | The Board Of Trustees Of The Leland Stanford Junior University | RNA fixation and detection in clarity-based hydrogel tissue |
RU2633490C1 (ru) * | 2016-11-23 | 2017-10-12 | Общество с ограниченной ответственностью "Медицина 3Д" | Материал для замещения дефектов мягких тканей |
PL241064B1 (pl) | 2018-10-01 | 2022-08-01 | Dolniak Blazej | Sposób wytwarzania lepko-sprężystego żelu uzupełniającego maź stawową i lepko-sprężysty żel uzupełniający maź stawową |
WO2023239695A1 (fr) * | 2022-06-06 | 2023-12-14 | Phrixionls, Llc | Prophylaxie et traitement de cartilage dégradé |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2088234C1 (ru) * | 1994-11-25 | 1997-08-27 | Институт высокомолекулярных соединений РАН | Водорастворимая бактерицидная композиция и способ ее получения |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3050012A1 (de) | 1979-11-06 | 1982-05-06 | I Bilko | Polyacrylamide gel for medical and biological application and method of its preparation |
UA10911C2 (uk) * | 1994-08-10 | 1996-12-25 | Мале Впроваджувальне Підприємство "Іhтерфалл" | Біосумісhий гідрогель |
US5941909A (en) * | 1995-02-14 | 1999-08-24 | Mentor Corporation | Filling material for soft tissue implant prostheses and implants made therewith |
US5658329A (en) * | 1995-02-14 | 1997-08-19 | Mentor Corporation | Filling material for soft tissue implant prostheses and implants made therewith |
RU2127095C1 (ru) * | 1996-05-28 | 1999-03-10 | Владислав Викторович Лопатин | Эндопротез молочной железы |
RU2127129C1 (ru) * | 1996-05-28 | 1999-03-10 | Владислав Викторович Лопатин | Способ получения гелеобразного материала для пластики мягких тканей |
RU2146127C1 (ru) * | 1996-08-07 | 2000-03-10 | Закрытое акционерное общество "Агрофарм-Питер-Сиб" | Мазь для лечения инфицированных ран |
BG102375A (en) * | 1997-08-26 | 1999-11-30 | Пегас Оод | Inoculation biocompatible hydrophilic gel, method for its preparation and application |
AU2001900A (en) * | 1999-12-29 | 2001-07-16 | Progen S.R.L. | Biocompatible hydrogel and method of its production |
-
2001
- 2001-09-28 US US10/490,969 patent/US7294348B2/en not_active Expired - Lifetime
- 2001-09-28 ES ES01274505T patent/ES2298195T3/es not_active Expired - Lifetime
- 2001-09-28 DE DE60132025T patent/DE60132025T2/de not_active Expired - Lifetime
- 2001-09-28 WO PCT/RU2001/000392 patent/WO2003026711A1/fr active IP Right Grant
- 2001-09-28 CA CA2461821A patent/CA2461821C/fr not_active Expired - Lifetime
- 2001-09-28 MX MXPA04002967A patent/MXPA04002967A/es active IP Right Grant
- 2001-09-28 RU RU2002102867/14A patent/RU2205034C1/ru not_active IP Right Cessation
- 2001-09-28 BR BRPI0117137-2A patent/BR0117137B1/pt not_active IP Right Cessation
- 2001-09-28 DK DK01274505T patent/DK1438976T3/da active
- 2001-09-28 CN CNB018236650A patent/CN1257752C/zh not_active Expired - Fee Related
- 2001-09-28 AT AT01274505T patent/ATE381356T1/de active
- 2001-09-28 EP EP01274505A patent/EP1438976B1/fr not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2088234C1 (ru) * | 1994-11-25 | 1997-08-27 | Институт высокомолекулярных соединений РАН | Водорастворимая бактерицидная композиция и способ ее получения |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Week 199826, Derwent World Patents Index; AN 1998-295476, XP002423139 * |
Also Published As
Publication number | Publication date |
---|---|
RU2205034C1 (ru) | 2003-05-27 |
DK1438976T3 (da) | 2008-04-28 |
WO2003026711A1 (fr) | 2003-04-03 |
BR0117137B1 (pt) | 2014-01-28 |
MXPA04002967A (es) | 2004-07-15 |
CA2461821C (fr) | 2011-03-15 |
EP1438976A1 (fr) | 2004-07-21 |
DE60132025T2 (de) | 2008-12-04 |
US7294348B2 (en) | 2007-11-13 |
US20040241241A1 (en) | 2004-12-02 |
ATE381356T1 (de) | 2008-01-15 |
DE60132025D1 (de) | 2008-01-31 |
BR0117137A (pt) | 2004-10-13 |
CA2461821A1 (fr) | 2004-04-03 |
CN1257752C (zh) | 2006-05-31 |
ES2298195T3 (es) | 2008-05-16 |
EP1438976B1 (fr) | 2007-12-19 |
CN1549732A (zh) | 2004-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003026711A1 (fr) | Hydrogel biocompatible polyfonctionnel et procede de production associe | |
US4409332A (en) | Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same | |
US5633001A (en) | Composition and a method for tissue augmentation | |
US5658593A (en) | Injectable compositions containing collagen microcapsules | |
CA1295259C (fr) | Procede permettant d'augmenter les tissus mous avec de la pyrrolidone polyvinylique reticulee | |
DE2706135A1 (de) | Verdickungsmittel fuer ausgeschiedenen darminhalt und harn | |
WO2006102676A1 (fr) | Elements de remplissage dermal d’oxyde de polyethylene et dispositifs associes | |
AU2001281763B2 (en) | Polyacrylamide hydrogel and its use as an endoprosthesis | |
KR101776675B1 (ko) | 콜라겐 하이드로겔 제조용 멀티 시린지 | |
WO2003084573A1 (fr) | Hydrogel biocompatible multifonctions et procede de fabrication correspondant | |
Firsov et al. | Biodegradable implants containing gentamicin: drug release and pharmacokinetics | |
CA2935110A1 (fr) | Materiau a vocation medicale a base d'hydrogel de polyacrylamide et procede de fabrication | |
CN101455628B (zh) | 一种眼用凝胶组合物的制备方法 | |
RU2127129C1 (ru) | Способ получения гелеобразного материала для пластики мягких тканей | |
WO2001049336A1 (fr) | Hydrogel biocompatible et procede de production | |
Gulchexra et al. | USING THE STATE-OF THE ART TECHNIQUES OF TEACHING BY CLASSIFICATION REPAIRING AND RECOVERING PROCESS OF SKIN BY BIOPOLYMERS IN MEDICAL AND ENGINEERING EDUCATION | |
Amudeswari et al. | Short‐term biocompatibility studies of hydrogel‐grafted collagen copolymers | |
RU2127095C1 (ru) | Эндопротез молочной железы | |
JP2004503483A (ja) | 低分子量ポリマー組成物 | |
МЕДИЦИНСКОМ | USING THE STATE-OF THE ART TECHNIQUES OF TEACHING BY CLASSIFICATION REPAIRING AND RECOVERING PROCESS OF SKIN BY BIOPOLYMERS IN MEDICAL AND ENGINEERING EDUCATION | |
Khule et al. | AS A REVIEW ON HYDROGEL IN PHARMACEUTICAL SCIENCES | |
AU2006220922B2 (en) | Polyacrylamide hydrogel and its use as an endoprosthesis | |
Valuev et al. | Growing polymer hydrogels | |
Reid | A histological evaluation of the biocompatibility of hydron implanted in Guinea pigs | |
US20050191271A1 (en) | Process for preparing alcoholic polyamide interpolymers in the form of biocompatible hydrogels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040426 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61L 27/16 20060101AFI20030408BHEP Ipc: A61L 27/54 20060101ALI20070308BHEP Ipc: A61L 27/52 20060101ALI20070308BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20070315 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 60132025 Country of ref document: DE Date of ref document: 20080131 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ROSENICH PAUL; GISLER CHRISTIAN PATENTBUERO PAUL R |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2298195 Country of ref document: ES Kind code of ref document: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20071219 |
|
ET | Fr: translation filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080519 |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: BIOFORM INTERNATIONAL S.A. |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20080922 |
|
NLT2 | Nl: modifications (of names), taken from the european patent patent bulletin |
Owner name: BIOFORM INTERNATIONAL S.A. Effective date: 20081015 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080320 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080929 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20071219 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080928 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20071219 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20180921 Year of fee payment: 18 Ref country code: DE Payment date: 20180925 Year of fee payment: 18 Ref country code: FR Payment date: 20180921 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20180920 Year of fee payment: 18 Ref country code: CH Payment date: 20180924 Year of fee payment: 18 Ref country code: AT Payment date: 20180918 Year of fee payment: 18 Ref country code: GB Payment date: 20180924 Year of fee payment: 18 Ref country code: SE Payment date: 20180924 Year of fee payment: 18 Ref country code: BE Payment date: 20180920 Year of fee payment: 18 Ref country code: DK Payment date: 20180924 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20181024 Year of fee payment: 18 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60132025 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20190930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190929 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20191001 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200401 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190930 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191001 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190930 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20190930 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 381356 Country of ref document: AT Kind code of ref document: T Effective date: 20190928 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190928 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190930 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20190928 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190930 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190930 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190928 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190928 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20210129 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190929 |